Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Predictors of Non-Stabilization during the Combination Therapy of Lithium and Divalproex in Rapid Cycling Bipolar Disorder: A Post-hoc Analysis of Two Studies
By Keming Gao, David E. Kemp, Zuowei Wang, Stephen J. Ganocy, Carla Conroy, Marry Beth Serrano, Martha Sajatovic, Robert L. Findling, Joseph R. Calabrese
Lamotrigine Adjunctive Therapy to Lithium and Divalproex in Depressed Patients with Rapid Cycling Bipolar Disorder and a Recent Substance Use Disorder:
A 12-week, Double-Blind, Placebo-Controlled Pilot Study
Zuowei Wang, Keming Gao, David E. Kemp, Philip K. Chan, Mary Beth Serrano, Carla Conroy, Yiru Fang, Stephen J. Ganocy, Robert L. Findling, Joseph R. Calabrese
Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010)
By Prakash S. Masand, MD, James Eudicone, MS, Andrei Pikalov, MD, PhD, Robert D. McQuade, PhD, Ronald N. Marcus, MD, Estelle Vester-Blokland, MD and Berit X. Carlson, PhD